DIP forges ¥30M+ AI pact with Imbioray Bio to power universal ACC-NK cell therapy

On January 26, Deep Intelligent Pharma (DIP), a globally leading AI-driven biotech unicorn, officially entered into a comprehensive strategic collaboration agreement with Imbioray Bio, a pioneering company in universal cell therapies.

The signing coincided with the unveiling of Imbioray's "Zhejiang Provincial Enterprise Research Institute" and the formal launch of its new Medical Research Center. Under the agreement, the two parties have jointly initiated the ACC-NK Cell Therapy AI Intelligent Platform, reaching a deep cooperation intent with a total value exceeding 300 million. As a comprehensive strategic partner, DIP will leverage its core Deep AI Scientist platform to provide robust AI computing power and algorithmic support for Imbioray's newly established Medical Research Center. Together, they aim to accelerate the global commercialization of the universal NK cell therapy (ACC-NK).

The signing of this strategic contract, valued in the hundreds of millions, marks the substantial implementation of the "AI + Biotech" model within a top-tier R&D platform.

On January 26, Imbioray held a grand ceremony at its Hangzhou headquarters to unveil its "Zhejiang Provincial Enterprise Research Institute" and was honored by the government as a "Quasi-Unicorn" company. As one of the first core technology partners for this high-level R&D platform, Deep Intelligent Pharma (DIP) will be deeply involved in Imbioray's R&D pipeline. The signing of this high-value strategic contract not only reflects Imbioray's strong recognition of DIP's AI technological capabilities but also signifies DIP's strategic shift from providing single-point technical services to forging deep, strategic partnerships with major clients.

Currently, both DIP and Imbioray are in a critical phase of rapid growth. Imbioray has emerged as a rising star in the cell therapy field, thanks to its first-in-class assets—IBR854 for solid tumors and IBR733 for AML (acute myeloid leukemia). DIP, with its unique approach of "AI-Defined Clinical Development," is reshaping the efficiency paradigm of drug R&D.

This collaboration will focus on addressing industry challenges such as the treatment of solid tumors and the scalable manufacturing of cell therapies. The powerful alliance between the two companies is also expected to jointly enhance their brand influence in the international market.

This collaboration has also garnered significant attention in the capital markets. Several industry analysts suggest that this model of deep integration between an "AI platform and innovative drug pipelines" could become a standard configuration for future innovative drug CRO companies.